Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Translational research 1

5155 - Tumor mutational burden and prognosis across pan-cancers


20 Oct 2018


Poster Discussion session - Translational research 1


Translational Research

Tumour Site

Colon and Rectal Cancer


Alberto Puccini


Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303


A. Puccini1, K. Poorman2, R. Goldberg3, A.F. Shields4, M. Winerip2, W.M. Korn5, M.D. Berger6, R. Tokunaga6, M. Naseem6, F. Battaglin6, W. Zhang7, S. Soni6, J.J. Hwang8, P. Philip4, J.L. Marshall9, H.J. Lenz6

Author affiliations

  • 1 Medical Oncology 1, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 2 Molecular Biology, Caris Life Sciences, Phoenix/US
  • 3 Medical Oncology, West Virginia University Cancer Institute, Morgantown/US
  • 4 Medical Oncology, Karmanos Cancer Institute, 48201-2013 - Detroit/US
  • 5 Molecular Biology, Caris Life Sciences, 85054 - Phoenix/US
  • 6 Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
  • 7 Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
  • 8 Hematology/medical Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte/US
  • 9 Lombardi Cancer Center, Georgetown University Hospital, 20007 - Washington DC/US

Abstract 5155


Disruption of epigenetic regulation in CRC, particularly aberrant histone methylation, has been shown to correlate with poorer survival rates in mCRC. We aimed to highlight the molecular differences between CRC harboring pathological mutations in genes involved in histone modification (KMT family).


Tumors were examined by NextGen sequencing, protein expression, and gene amplification. Tumor mutational burden (TMB) was calculated based on somatic missense mutations (TMB-high ≥ 17 mt/MB) and microsatellite instability (MSI) was evaluated on known MSI loci in the target regions. Chi-square and t-tests were used for comparative analyses.


In total, 3621 CRC were examined, and 224 (6.2%) showed a pathological mutation in KMT2A, KMT2C, or KMT2D. Demographics were as follow: F/M 47%/53%, median age 60. KMT mutations were strongly associated with MSI-H (66.5% vs 2.5%, P<.0001), TMB-high (72% vs 3%, P<.0001), BRAF mutation (24.7% vs 7.5%, P<.0001), PD-L1 overexpression (14.2% vs 2.7%, P<.0001), right-sided (11.7% vs 3.4% in left-sided tumors, P = 0.001) and POLE mutations (6.7% vs 0.1%, P<.0001). Furthermore, the rate of mutations among several genes such as ATM, ATRX, BRCA1/2, MLH1, MSH2/6, PMS2 (all P < 0.001) were more frequently seen in the KMT mutated tumors. All remained significant after multiple test correction. When we analyzed MSS tumors and POLE non-mutant tumors excluding MSI-H or POLE mutation, TMB-H remains more frequent in tumors with KMT mutations (8.3% vs 0.9%, P = 0.004), as well as several genes were more frequently mutated in KMT mutated tumors compared to WT tumors (CDC73, 1.7% vs 0.0%, P=.003; KDR, 1.7% vs 0.03%, P=.011; SDHB, 1.7% vs 0.1%, P=.023; PRKDC, 1.7% vs. 0.1%, P=.046; CHEK2, 5.6% vs 1.4%, P=.049).


Our findings provide the first exploratory data on KMT genes mutations and their association with clinical and molecular features in CRC, in a large population of patients. Further investigations are warranted to elucidate the association between TMB-H and histone modifications, potentially leading to a better understanding of epigenetic alterations in CRC and to identify novel targets for therapeutic options for CRC patients.

Clinical trial identification

Legal entity responsible for the study

Heinz-Josef Lenz.


Has not received any funding.

Editorial Acknowledgement


K. Poorman, M. Winerip, W.M. Korn: Employee: Caris Life Sciences. J.L. Marshall: Consultant: Caris Life Sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.